Vertex Pharmaceuticals Incorporated VRTX
Set alert
At close · Oct 30
After hours · Oct 30, 5:48 PM ET
- YTD
- +23.28%
- 1 year
- +33.10%
- Open
- 550.73
- Prev close
- 540.00
- Mkt cap
- 141.56B
- Vol
- 3.03M
- Avg vol
- 1.16M
- EPS
- 17.17
- P/E
- 32.55
- Div yield
- 0.00%
More statistics
- Low
- 549.89
- High
- 563.80
- Forward P/E
- 27.40
- Beta
- 0.28
- Short ratio
- 3.66
- Inst. own
- 98.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 522.84
- 200-d avg
- 478.67
- 1y target
- 571.46
5D chart
Signals (141)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:50 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:35 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:15 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 3:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:10 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:50 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:35 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 11:50 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:20 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:05 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| RSI: Oversold | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 5 days ago |
News
2 days ago benzinga.com
Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 4.68% on an annualized basis producing an average annual return of 13.63%. Currently, Vertex Pharmaceuticals…
3 days ago zacks.com
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key…
3 days ago zacks.com
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
4 days ago fool.com
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight…
4 days ago zacks.com
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
5 days ago zacks.com
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.
5 days ago zacks.com
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago 247wallst.com
The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on…
5 days ago seekingalpha.com
Baron Health Care Fund: Q3 2026 New Positions And Exits
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early…
1 week ago fool.com
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
The biotech company has grown its annual revenue by more than 600% over the past decade. Kidney disease therapy inaxaplin is seen as a possible blockbuster drug.
1 week ago seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
-
1 week ago benzinga.com
Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN…
1 week ago businesswire.com
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM),…
1 week ago fool.com
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Both of these ETFs look the part, but only one is truly the better buy for investors.
1 week ago zacks.com
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.
1 week ago fool.com
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie generates massive free cash flow while successfully navigating the loss of exclusivity for its top-selling drug. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis…
1 week ago businesswire.com
Vertex Appoints Daniel Brennan to its Board of Directors
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan…
2 weeks ago defenseworld.net
3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Banque Pictet and Cie SA trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 15.7% in the undefined quarter, according to the company in its most recent 13F filing with the…
2 weeks ago zacks.com
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 weeks ago zacks.com
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.
2 weeks ago fool.com
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.
2 weeks ago fool.com
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Moderna is leveraging its mRNA platform to expand beyond COVID-19 vaccines into RSV and oncology therapeutics. Vertex Pharmaceuticals maintains market dominance in cystic fibrosis while successfully…
-
3 weeks ago benzinga.com
Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also…
3 weeks ago benzinga.com
If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals…
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.
3 weeks ago benzinga.com
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
1 month ago benzinga.com
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.
-
1 month ago benzinga.com
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.
1 month ago benzinga.com
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.
-
1 month ago benzinga.com
Vertex Pharmaceuticals Announces Results From Phase 2b AMPLIFIED Study Of Inaxaplin In People With Kidney Disease And Type-2 Diabetes; Treatment With Inaxaplin Led To Reduction In Urine Albumin To Creatinine Ratio Of -42.7% At Week 13 Compared To Baseline; Inaxaplin Was Generally Safe And Well Tolerated In Both Cohorts
Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.In this study, inaxaplin was evaluated as…
1 month ago benzinga.com
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals…
-
1 month ago benzinga.com
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
-
2 months ago benzinga.com
If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals…
2 months ago benzinga.com
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’
CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).
-
2 months ago benzinga.com
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals…
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.
-
2 months ago benzinga.com
Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est
Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.
-
2 months ago benzinga.com
Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate
Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the…
2 months ago benzinga.com
Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.
2 months ago benzinga.com
Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone
CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.
3 months ago benzinga.com
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
-
3 months ago benzinga.com
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals…
-
3 months ago benzinga.com
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.
3 months ago benzinga.com
Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’
The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young Thomas, and Joseph M. Terranova.